Literature DB >> 26805322

[Usefulness of Metallic Stent for Left-Sided Obstructive Colon Cancer].

Yosuke Shimizu1, Harumi Tominaga, Shinya Yamashita, Yuri Kimura, Kazuki Odagiri, Tomoaki Kurokawa, Megumi Yamaguchi, Gen Takahashi, Genta Sawada, Masashi Inoue, Moon Jeongho, Toshimitsu Irei, Shin Nakahira, Nobutaka Hatanaka.   

Abstract

The aim of this study was to compare the efficacy of self-expandable metallic stent (SEMS) and transanal tube as preoperative treatments for left-sided obstructive colon cancer. Forty-three patients (the SEMS group: 28 cases, the tube group: 15 cases) were included in this study. Clinicopathological data (age, sex, tumor location, depth, histological type, stage) were comparable between the 2 groups. In addition, there was no difference in intestinal decompression rate between the SEMS group and the tube group (technical success rate: 100% vs 86.7%, clinical success rate: 92.8% vs 73.3%, complication rate: 7.1% vs 0%). A significantly higher number of patients in the SEMS group underwent laparoscopic surgery because of difference of historical background. However, no significant difference was observed between the 2 groups in postoperative outcome(complication rate, hospital stay duration). SEMS insertion had several benefits compared to transanal tube placement, such as the resumption of oral intake because of rapid resolution of obstruction and easier management because SEMSs do not require washing. SEMS insertion could be a safe and effective bridge to subsequent surgery in patients with left-sided obstructive colon cancer.

Entities:  

Mesh:

Year:  2015        PMID: 26805322

Source DB:  PubMed          Journal:  Gan To Kagaku Ryoho        ISSN: 0385-0684


  1 in total

1.  Impact of endoscopic stent insertion on detection of viable circulating tumor cells from obstructive colorectal cancer.

Authors:  Shinya Yamashita; Masahiro Tanemura; Genta Sawada; Jeongho Moon; Yosuke Shimizu; Toshiki Yamaguchi; Toshio Kuwai; Yasuo Urata; Kazuya Kuraoka; Nobutaka Hatanaka; Yoshinori Yamashita; Kiyomi Taniyama
Journal:  Oncol Lett       Date:  2017-11-02       Impact factor: 2.967

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.